Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY3003
- Development stage
- Preclinical
- Lead developer
- Hybio Pharmaceutical
- Modality
- Peptides
- Administration
- Subcutaneous, Oral
01
Overview
HY3003 is a triple agonist peptide innovative drug being developed by Hybio Pharmaceuticals in collaboration with iCarbonX. It targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) to provide multi-hormonal metabolic effects for the treatment of obesity, type 2 diabetes, and other metabolic diseases. Discovered using AI-integrated peptide chip technology, the drug is currently in preclinical development. The development program includes a monthly subcutaneous long-acting sustained-release injectable formulation and an oral formulation.
02
Targets
Beyond the preview
Go deeper on HY3003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY3003.